CD8A and cancer: When tested on primary human lymphocytes activated with αCD3/28 beads ± rhIL2, pevonedistat demonstrated a negative impact on the proliferation of CD4+ T cells, CD8+ T cells and NK cells with comparable potencies as observed in cancer cells, i.e., between 100 nM and 600 nM (Fig. 5b).